Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
about
Prognostic molecular markers in early breast cancerIdentification of a three-gene expression signature of poor-prognosis breast carcinomaCandidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitorsConnexins, gap junctions and tissue invasionPlasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineProspective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease.Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycleAssessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future ProspectsThe Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer.St. Gallen 2011: Summary of the Consensus Discussion.Chemoendocrine Treatment Is Standard in Hormone Receptor-Positive Patients.Node-Negative Breast Cancer: Which Patients Should Be Treated?Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues.Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancerThe changing role of pathology in breast cancer diagnosis and treatment.Adjuvant Systemic Therapy of Breast Cancer.Tumor markers: from laboratory to clinical utility.uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.The patient experiencePleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort studyuPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.Non-invasive proteomics-thinking about personalized breast cancer screening and treatmentPrognostic factors for breast cancer and their use in the clinical setting.Biomarkers in Breast Cancer - An UpdateTumor markers in breast cancer- European Group on Tumor Markers recommendations.Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancerIndependent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patientsPhase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancerRisk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexesBlood biomarkers for prostate cancer detection and prognosis.
P2860
Q24794845-7112E81F-BAFD-48EE-8348-8C74D6FC95E0Q24802692-A9DB0A51-A78F-459F-AB16-A7012E788C49Q26830522-48E7E476-CBDB-4621-869B-B8EC4510AB11Q26861688-19DA8A53-C71B-4D13-90B7-7E9DEBB1C2B9Q28067626-8158B617-C8F7-4184-9785-E4C599A2FC33Q30318419-454F6DBA-9304-4CC4-9EF8-32C35F11306EQ33186595-CBE666EA-3923-4763-BBD5-FC8F77DE363CQ33255953-71612848-AF08-4F3A-86D2-34F79EAAF180Q33695003-FA2D29EC-E1CE-4BE2-8596-743EF83D2CCAQ33715393-AF7C537B-1035-4DD3-9630-11AD7307E37EQ34095769-E1F7C551-D112-445D-AD08-F723EA2F1AABQ34095782-A3D4038B-3AD6-4932-A94D-DAB9BDF23845Q34095789-E7E31346-C1D7-47CC-9080-8D10766C7954Q34189116-59C80DF3-374D-4E59-B401-AF0644B91E1BQ34284254-6FF44466-D3AA-43AF-8D93-2E566AF05ECAQ34284270-F41A78E4-9341-4692-8E0B-B7C155EC1FC9Q34422523-9B9D90CE-D7C3-4DD6-9CCE-22E5B6090310Q34434875-BCDF78C0-4AB3-440F-8A1A-DB74523E05BDQ34653166-B6D970DA-D4D3-4A74-97BD-179D25A5EC15Q34997475-FBC339EB-12DC-4053-8530-64EA2E07A3EFQ35082260-E73D548A-5061-4A43-95AD-EB5B2FD5CE82Q35095595-82A5E781-E223-4F0A-A23A-C54391708CF7Q35157034-673F49C2-5790-4008-8134-BCB6B128A46AQ35580701-743EB587-C081-449B-9427-29484BD583A0Q35751445-1B32F1B7-1467-4538-9DFD-8E100BEDD899Q36026414-698D4A4D-C51C-4C75-A190-D8692A9CC859Q36076565-3F7B01E6-A58D-4386-B420-7A2367A8F669Q36097941-61F3ADFD-702B-48B0-91B4-2B7B064229CEQ36117711-43E95BDF-B0BC-4C50-9203-B817DA709398Q36118398-3D0D4BF5-B1DB-4FF0-85E3-F127EA3DCECEQ36295142-37EF133F-0FAF-460B-8EDB-7DACF432B68AQ36299309-2E92A84D-B91D-486C-BD46-96227E6B071AQ36490382-1C17A460-58DC-4B98-B8F8-70E99C3F263EQ36647801-D5FFF682-1205-40E2-832F-779B43038C5DQ36647843-1333B2E6-D0AA-4B67-A80A-B2893A60F0D6Q36663677-0309D122-BD6D-4BAD-BB0B-46051D8E6458Q36738790-47E4DE95-6809-496A-9130-FC43B7918714Q36761523-8C98CCF0-AAF8-472E-80C7-980278F4C7CDQ36803178-A5FFA51F-376E-4269-8E80-46F6E0181020Q36895818-5899DADC-7EE9-47A7-97AA-93D15E31CF8A
P2860
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Randomized adjuvant chemothera ...... en activator inhibitor type 1.
@en
Randomized adjuvant chemothera ...... en activator inhibitor type 1.
@nl
type
label
Randomized adjuvant chemothera ...... en activator inhibitor type 1.
@en
Randomized adjuvant chemothera ...... en activator inhibitor type 1.
@nl
prefLabel
Randomized adjuvant chemothera ...... en activator inhibitor type 1.
@en
Randomized adjuvant chemothera ...... en activator inhibitor type 1.
@nl
P2093
P356
P1476
Randomized adjuvant chemothera ...... en activator inhibitor type 1.
@en
P2093
C Thomssen
German N0 Study Group
H K Selbmann
P304
P356
10.1093/JNCI/93.12.913
P407
P577
2001-06-01T00:00:00Z